Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

Published:2018-08-18 Issue:2 Volume:5 Page:447-462
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Kivitz Alan J.,Wagner Ulf,Dokoupilova Eva,Supronik Jerzy,Martin Ruvie,Talloczy Zsolt,Richards Hanno B.,Porter Brian

Funder

Novartis Pharma AG

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s40744-018-0123-5.pdf

Reference19 articles.

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379–90.

2. Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–37.

3. Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014;28:663–72.

4. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904.

5. van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978–91.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-17 inhibitors in axial spondyloarthritis. An overview;Expert Opinion on Biological Therapy;2024-08-21

2. A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment;Rheumatology;2024-08-12

3. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis;Frontiers in Immunology;2024-07-15

4. Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis;Rheumatology and Therapy;2024-06-25

5. An update in the pharmacological management of axial spondyloarthritis;Expert Opinion on Pharmacotherapy;2024-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3